Daily recombinant human growth hormone revolutionized the treatment ‎of growth hormone deficiency and has been the standard of care since ‎the 1980s.  However, the burden of daily injections and reduction in ‎treatment outcomes from nonadherence have prompted the ‎development of long-acting growth hormone analogs.  Currently, LAGH ‎analogs are marketed in Asia and just recently in the United States for ‎pediatric growth hormone deficiency.  This new era of growth hormone ‎treatment brings the potential of increased tolerability, therapeutic ‎flexibility and adherence.  However, the unphysiological nature and ‎differences in the technology used to prolong GH may also bring certain ‎challenges to dosing, monitoring and long-term safety.‎

The presenters will provide tools and understanding of how patients with ‎diabetes using technology can be managed in the hospital. This panel will ‎include presenters from different practices and how they approach this ‎topic. Attendees will learn how they can advocate for patients to use ‎their medically necessary tools that promote optimal glycemic control in ‎the hospital.‎

Turner syndrome (TS) is the most common sex chromosome disorder in ‎females. Individuals with TS commonly have ovarian failure, leading to ‎absence of puberty and menstruation. They need estrogen/progestin ‎therapy to induce puberty and maintain the secondary sexual ‎characteristics. Endocrine providers often deal with TS patients in the ‎clinic setting. Prescribing estrogens to induce puberty can be associated ‎with abnormal uterine bleeding (AUB), especially with the use of (low-‎dose) transdermal estrogens. In their different roles, both advance nurse ‎practitioners and endocrine nurses will, at some point, encounter TS ‎patients with AUB. Using the clinical experience of the TS team at ‎Cincinnati Children’s Hospital, which follows a very large population of TS ‎patients, together with data from a recently completed research project, ‎and illustrated further by case presentations, the speakers intend to ‎inform the audience on the diagnosis, management and educational ‎aspects related to AUB in TS individuals. The nurse-coordinator will ‎address the counseling issues and provide the nursing perspective on ‎how to deal with the testing/procedures these patients may need, and ‎how    follow-up should be addressed. The MD presenter will review ‎recently obtained data on the risk factors associated with AUB and how ‎to address AUB therapeutically. The presentation will therefore combine ‎clinic experience, with research data, as well as provide practice ‎recommendations based on recently developed consensus guidelines.    ‎With the increased use of the newer transdermal estrogen preparations, ‎while the optimal replacement regimen has not been defined yet, this ‎presentation will be very helpful for all health care personnel interacting ‎with these patients as they present with AUB.     ‎